Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Moderna’s stock doubles on promising cancer-vaccine results marketwatch.com
